Search Results - "Weinreb, J"

Refine Results
  1. 1

    Spinal cord injury models: a review by Cheriyan, T, Ryan, D J, Weinreb, J H, Cheriyan, J, Paul, J C, Lafage, V, Kirsch, T, Errico, T J

    Published in Spinal cord (01-08-2014)
    “…Background: Animal spinal cord injury (SCI) models have proved invaluable in better understanding the mechanisms involved in traumatic SCI and evaluating the…”
    Get full text
    Journal Article
  2. 2

    Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: A study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry by Khan, Aneal, Hangartner, Thomas, Weinreb, Neal J, Taylor, John S, Mistry, Pramod K

    Published in Journal of bone and mineral research (01-08-2012)
    “…We hypothesized that overall disease activity or the severity of involvement of individual disease compartments, as measured by clinical and surrogate markers,…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Gaucher disease and cancer incidence: a study from the Gaucher Registry by Rosenbloom, Barry E., Weinreb, Neal J., Zimran, Ari, Kacena, Katherine A., Charrow, Joel, Ward, Elizabeth

    Published in Blood (15-06-2005)
    “…Patients with Gaucher disease (GD) are alleged to be at an increased risk of malignant disorders, possibly due to potential chronic stimulation of the immune…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Therapeutic goals in the treatment of Gaucher disease by Pastores, Gregory M., Weinreb, Neal J., Aerts, Hans, Andria, Generoso, Cox, Timothy M., Giralt, Manuel, Grabowski, Gregory A., Mistry, Pramod K., Tylki-Szymańska, Anna

    Published in Seminars in hematology (01-10-2004)
    “…Gaucher disease, the most common lysosomal storage disorder, is a heterogeneous multisystem condition. Patients with non-neuronopathic (type 1) Gaucher disease…”
    Get full text
    Journal Article
  7. 7
  8. 8

    The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease by Charrow, J, Dulisse, B, Grabowski, GA, Weinreb, NJ

    Published in Clinical genetics (01-03-2007)
    “…The effect of enzyme replacement therapy (ERT) on bone crisis and bone pain was investigated in patients with Gaucher disease (GD) type 1 followed over 4…”
    Get full text
    Journal Article
  9. 9

    The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease by Hollak, Carla E.M., MD, PhD, Weinreb, Neal J., MD

    “…Enzyme replacement therapies have been developed and authorized for commercial use for six different lysosomal storage disorders. For Gaucher disease, Fabry…”
    Get full text
    Journal Article
  10. 10

    Patients with Gaucher disease display systemic oxidative stress dependent on therapy status by Kartha, Reena V., Terluk, Marcia R., Brown, Roland, Travis, Abigail, Mishra, Usha R., Rudser, Kyle, Lau, Heather, Jarnes, Jeanine R., Cloyd, James C., Weinreb, Neal J.

    Published in Molecular genetics and metabolism reports (01-12-2020)
    “…Gaucher disease is an autosomal recessive metabolic disorder caused by mutations in GBA1, which encodes for the lysosomal hydrolase enzyme,…”
    Get full text
    Journal Article
  11. 11

    The international cooperative Gaucher group (ICCG) Gaucher registry by Weinreb, Neal J

    “…Gaucher disease GD), is a rare lysosomal storage disorder caused by deficient acid β-glucosylceramidase activity and accumulation of glucosylceramide in tissue…”
    Get full text
    Journal Article
  12. 12

    Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study by Sims, KB, Pastores, GM, Weinreb, NJ, Barranger, J, Rosenbloom, BE, Packman, S, Kaplan, P, Mankin, H, Xavier, R, Angell, J, Fitzpatrick, MA, Rosenthal, D

    Published in Clinical genetics (01-05-2008)
    “…Progressive skeletal disease accounts for some of the most debilitating complications of type 1 Gaucher disease. In this 48‐month, prospective, non‐randomized,…”
    Get full text
    Journal Article
  13. 13

    Abdominal MR imaging with a volumetric interpolated breath-hold examination by Rofsky, N M, Lee, V S, Laub, G, Pollack, M A, Krinsky, G A, Thomasson, D, Ambrosino, M M, Weinreb, J C

    Published in Radiology (01-09-1999)
    “…To compare a T1-weighted, three-dimensional (3D), gradient-echo (GRE) sequence for magnetic resonance (MR) imaging of the body (volumetric interpolated…”
    Get more information
    Journal Article
  14. 14

    Skeletal aspects of Gaucher disease: a review by WENSTRUP, R. J, ROCA-ESPIAU, M, WEINREB, N. J, BEMBI, B

    Published in British journal of radiology (01-01-2002)
    “…In Gaucher disease, a genetic deficiency in the activity of the lysosomal enzyme beta-glucocerebrosidase (acid beta-glucosidase) causes monocytes and…”
    Get full text
    Conference Proceeding Journal Article
  15. 15

    Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation by Krinsky, G A, Lee, V S, Theise, N D, Weinreb, J C, Rofsky, N M, Diflo, T, Teperman, L W

    Published in Radiology (01-05-2001)
    “…To determine the sensitivity and specificity of magnetic resonance (MR) imaging for detection of hepatocellular carcinoma (HCC) and dysplastic nodules (DNs) by…”
    Get more information
    Journal Article
  16. 16
  17. 17

    Breath-hold single-dose gadolinium-enhanced three-dimensional MR aortography: usefulness of a timing examination and MR power injector by Earls, J P, Rofsky, N M, DeCorato, D R, Krinsky, G A, Weinreb, J C

    Published in Radiology (01-12-1996)
    “…To determine the usefulness of a timing examination performed with 1 mL gadopentetate dimeglumine administered with a magnetic resonance (MR) power injector at…”
    Get more information
    Journal Article
  18. 18

    Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease by Goker-Alpan, Ozlem, Gambello, Michael J., Maegawa, Gustavo H. B., Nedd, Khan J., Gruskin, Daniel J., Blankstein, Larry, Weinreb, Neal J.

    Published in JIMD Reports, Volume 25 (01-01-2016)
    “…Introduction: Agalsidase alfa and agalsidase beta, recombinant enzyme preparations for treatment of Fabry disease (FD), have different approved dosing…”
    Get full text
    Book Chapter Journal Article
  19. 19

    A validated disease severity scoring system for adults with type 1 Gaucher disease by Weinreb, Neal J., Cappellini, Maria D., Cox, Timothy M., Giannini, Edward H., Grabowski, Gregory A., Hwu, Wuh-Liang, Mankin, Henry, Martins, Ana Maria, Sawyer, Carolyn, Vom Dahl, Stephan, Yeh, Michael S., Zimran, Ari

    Published in Genetics in medicine (01-01-2010)
    “…A validated disease severity scoring system (DS3) for Gaucher disease type 1 (GD1) is needed to standardize patient monitoring and to define patient cohorts in…”
    Get full text
    Journal Article
  20. 20

    MR imaging of the breast by Weinreb, J C, Newstead, G

    Published in Radiology (01-09-1995)
    “…Studies suggest that magnetic resonance (MR) imaging may have a variety of roles in the detection and management of breast disease. However, because study…”
    Get more information
    Journal Article